Researchers previously reported promising results in adolescents and young adults with XSCID who were treated with the St. Jude vector and low - dose
chemotherapy after bone marrow transplantation failed to restore adequate immune protection.
Although we were able to now detect more distinct T and B cell populations in the transplanted immunocompetent MRL and 129SvJ mice, the numbers of lymphoid cells remained far less than would be
expected after bone marrow transplantation.